ARNA

Arena Pharmaceuticals Stock Price

85.50
4.16 (5.11%)
Upgrade to Real-Time
Afterhours (Closed)
85.50
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Arena Pharmaceuticals Inc ARNA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
4.16 5.11% 85.50 16:40:23
Close Price Low Price High Price Open Price Previous Close
85.50 80.01 86.14 80.19 81.34
Bid Price Ask Price Spread News
71.64 85.35 13.71 1 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
13,732 1,183,491 $ 84.44 $ 99,939,822 639,099 32.95 - 86.58
Last Trade Time Type Quantity Stock Price Currency
18:33:24 1 $ 85.35 USD

Arena Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 4.93B 57.65M 57.60M $ 806.43M $ - 7.70 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Arena Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ARNA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week81.0786.1475.9878.40578,3134.435.46%
1 Month74.1786.5873.40578.89599,48411.3315.28%
3 Months61.8186.5861.4772.02547,47623.6938.33%
6 Months52.6686.5844.7965.02640,31332.8462.36%
1 Year49.0086.5832.9556.58576,85936.5074.49%
3 Years26.9486.5824.3347.25606,45358.56217.37%
5 Years22.6086.5811.3027.491,044,88162.90278.32%

Arena Pharmaceuticals Description

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.